Form 4: Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Executes Stock Option and Sells Shares

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 16, 2024, Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences, exercised non-qualified stock options to acquire 7,004 shares of common stock at a price of $79.02 per share.
• Simultaneously, Lippoldt sold 7,004 shares of common stock at a weighted average price of $149.9986 per share, with individual sales prices ranging from $149.80 to $150.24.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 24, 2023.
• Following these transactions, Lippoldt directly owns 39,740 shares of Neurocrine Biosciences common stock and holds options for 46,368 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to use Rule 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a standard part of executive compensation and portfolio management.

Comparison to Industry Standards

• Executive stock option exercises and sales are common in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings from their executives.
• The use of Rule 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the sales were pre-planned and not based on current inside information.

Key Dates